Search JIM Advanced Search

Journal of Chinese Integrative Medicine ›› 2009, Vol. 7 ›› Issue (4): 306-308.doi: 10.3736/jcim20090402

• Original Clinical Research • Previous Articles     Next Articles

Thinking on syndrome differentiation treatment and personalized therapy for tumor

Jing Li   

  1. Department of Traditional Chinese Medicine, the Fourth Hospital, Hebei Medical University, Shijiazhuang 050011,Hebei Province, China
  • Received:2008-12-04 Accepted:2009-02-04 Online:2009-04-20 Published:2009-04-15

The concepts of Western medicine in treating tumor have changed markedly in recent years, and begun to put more emphasis on the whole survival status of patients. With recent emergence of targeted drugs, it was found that curative effects of the same targeted drugs in treating patients with the same tumor type even the same tumor pathological subtype but different therapeutic targets may be different. On the contrary, the curative effects of different targeted drugs in treating patients with different tumor types but the same therapeutic targets may be similar. Accordingly, the viewpoint of personalized therapy is advocated in Western medicine. Under the guidance of syndrome differentiation treatment in traditional Chinese medicine (TCM), patients with the same tumor and different syndromes should be treated by different herbs, and patients with different tumor and the same syndrome should be treated by the same herbs. Both the theories of "the same treatment for the same syndrome" and "the same treatment for the same therapeutic target" indicate that personalized therapy in Western medicine is similar to TCM syndrome differentiation treatment. The article focuses on "different treatments for the same disease" as well as "the same treatment for different diseases" to describe the similar points between personalized therapy and TCM syndrome differentiation treatment and thereby proves that TCM syndrome differentiation treatment is a scientific and essential approach in treating tumor. At the same time, the article also points out the problems and solution methods of TCM syndrome differentiation treatment.

Key words: Syndrome differentiation treatment, Personalized therapy, Neoplasms, Traditional Chinese medicine

[1] Zhang XY, Xu LY, Wang H, Zhu YZ, Liu Z, Yue WT, Tang JF, Wu W, Liu Z, Wu YH, Zhang CY, Shi YK, Wang MZ, Shi HL, Li MZ, Meng QY, Guo LL, Wang JH, Li XB . The relationship between EGFR mutations and response and prognosis of tyrosine kinase inhibitors in advanced non-small-cell lung cancer[J]. Zhongguo Fei Ai Za Zhi, 2008,11(2):206-213
张新勇, 徐丽艳, 汪惠, 朱允中, 刘喆, 岳文涛, 唐俊舫, 武玮, 刘赞, 吴羽华, 张春彦, 石远凯, 王孟昭, 史鹤玲, 李明智, 孟弃逸, 郭丽丽, 王敬慧, 李雪冰 . EGFR基因突变与酪氨酸激酶抑制剂疗效及预后之间的关系[J]. 中国肺癌杂志, 2008,11(2):206-213
[2] Liu YF, Guan XX, Chen LB, Chen YT . Study on ERCC1, XPD and XPA polymorphisms for prediction of platinum-based chemotherapy sensitivity in non-small cell lung cancer[J]. Zhonghua Zhong Liu Fang Zhi Za Zhi, 2008,15(17):1285-1288
柳艳飞, 管晓翔, 陈龙邦, 陈一天 . ERCC1与XPD和XPA的遗传多态性对非小细胞肺癌铂类化疗敏感性预测的研究[J]. 中华肿瘤防治杂志, 2008,15(17):1285-1288
[3] Meng FY, Zheng WY, Liu XL, Song LL, Xu B, Zhang Y . Clinical observation of curative effects of imatinib in treatment of 26 cases of chronic myeloid leukemia[J]. Zhonghua Xue Ye Xue Za Zhi, 2004,25(5):314-315
孟凡义, 郑维扬, 刘晓力, 宋兰林, 徐兵, 张钰 . 伊马替尼治疗慢性粒细胞白血病26例临床观察[J]. 中华血液学杂志, 2004,25(5):314-315
[4] Xu WT, Li R . Efficacy of imatinib mesylate in treatment of advanced gastrointestinal stromal tumors[J]. Di Er Jun Yi Da Xue Xue Bao, 2005,26(5):583-584
徐文通, 李荣 . 甲磺酸伊马替尼治疗晚期胃肠道恶性间质瘤疗效的初步观察[J]. 第二军医大学学报, 2005,26(5):583-584
[5] Ma D . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J]. Xun Zheng Yi Xue, 2006,6(5):277-280
doi: 10.3969/j.issn.1671-5144.2006.05.007
马冬 . 贝伐单抗联合依立替康、氟尿嘧啶/甲酰四氢叶酸对转移性结直肠癌的治疗[J]. 循证医学, 2006,6(5):277-280
doi: 10.3969/j.issn.1671-5144.2006.05.007
[6] Wang T, Luo LL . A systematic review of bevacizumab for non-small cell lung cancer[J]. Zhongguo Shi Yong Yi Yao, 2008,3(5):1-2
王艇, 罗黎力 . 贝伐单抗治疗晚期非小细胞肺癌的系统评价[J]. 中国实用医药, 2008,3(5):1-2
[1] Wan-jun Guo, Yi Wang, Yu Deng, Lin-yan Cheng, Xin Liu, Ruo-fan Xi, Sheng-jie Zhu, Xin-yi Feng, Liang Hua, Kan Ze, Jian-yong Zhu, Dong-jie Guo, Fu-lun Li. Therapeutic effects of the extract of Sancao Formula, a Chinese herbal compound, on imiquimod-induced psoriasis via cysteine-rich protein 61. Journal of Integrative Medicine, 2022, 20(4): 376-384.
[2] Shang-jin Song, Xuan Liu, Qing Ji, Da-zhi Sun, Li-juan Xiu, Jing-yu Xu, Xiao-qiang Yue. Ziyin Huatan Recipe, a Chinese herbal compound, inhibits migration and invasion of gastric cancer by upregulating RUNX3 expression. Journal of Integrative Medicine, 2022, 20(4): 355-364.
[3] Marisa Casal. Improving the health and treatment success rates of in vitro fertilization patients with traditional chinese medicine: need for more robust evidence and innovative approaches. Journal of Integrative Medicine, 2022, 20(3): 187-192.
[4] Ning Guo, Fei Wu, Mei Wu, Yuan Wang, Qing Lang, Xiao Lin, Yi Feng. Progress in the design and quality control of placeboes for clinical trials of traditional Chinese medicine . Journal of Integrative Medicine, 2022, 20(3): 204-212.
[5] Yan-jun Lin, Kun-li Jiao, Bo Liu, Lu Fang, Shu Meng. Antiplatelet and myocardial protective effect of shexiang tongxin dropping pill in patients undergoing percutaneous coronary intervention: A randomized controlled trial. Journal of Integrative Medicine, 2022, 20(2): 126-134.
[6] Jia-jia Li, Qing Liang, Guang-chun Sun. Traditional Chinese medicine for prevention and treatment of hepatocellular carcinoma: A focus on epithelial-mesenchymal transition. Journal of Integrative Medicine, 2021, 19(6): 469-477.
[7] Rui-jin Qiu, Min Li, Jia-yuan Hu, Jing Chen, Hong-cai Shang. Methods for development of a core outcome set for clinical trials integrating traditional Chinese medicine and Western medicine. Journal of Integrative Medicine, 2021, 19(5): 389-394.
[8] Mao-xing Pan, Chui-yang Zheng, Yuan-jun Deng, Kai-rui Tang, Huan Nie, Ji-qian Xie, Dong-dong Liu, Gui-fang Tu, Qin-he Yang, Yu-pei Zhang. Hepatic protective effects of Shenling Baizhu powder, a herbal compound, against inflammatory damage via TLR4/NLRP3 signalling pathway in rats with nonalcoholic fatty liver disease . Journal of Integrative Medicine, 2021, 19(5): 428-438.
[9] Ning Zhang, Xiao-he Xiao. Integrative medicine in the era of cancer immunotherapy: Challenges and opportunities. Journal of Integrative Medicine, 2021, 19(4): 291-294.
[10] Thomas Efferth, An-long Xu, Roxana Damiescu, Mita Banerjee, Norbert W. Paul, David Y.W. Lee. Can eastern wisdom resolve western epidemics? Traditional chinese medicine therapies and the opioid crisis. Journal of Integrative Medicine, 2021, 19(4): 295-299.
[11] Si-qi Tang, Yun-liang Wang, Zi-ye Xie, Yang Zhang, Yi Guo, Kang-li Gao, Tang-you Mao, Chun-e Xie, Jun-xiang Li, Xiao-yan Gao. Serum metabolic profiling of traditional Chinese medicine syndromes in patients with diarrhea-predominant irritable bowel syndrome. Journal of Integrative Medicine, 2021, 19(3): 274-281.
[12] Miao-yan Shi, Shi-qi Sun, Wei Zhang, Xing Zhang, Gui-hua Xu, Xuan Chen, Zi-jian Su, Xiu-ming Song, Lu-jiong Liu, Yi-bao Zhang, Yi-le Zhang, Meng Sun, Qi Chen, Yan Xue, Hua Lü, Wei-an Yuan, Xiao-rong Chen, Yun-fei Lu. Early therapeutic interventions of traditional Chinese medicine in COVID-19 patients: a retrospective cohort study. Journal of Integrative Medicine, 2021, 19(3): 226-231.
[13] Shu-jun Wei, Qing-man He, Qing Zhang, Kang-hua Fu, Ruo-lan Li, Wei Peng, Yong-xiang Gao. Traditional Chinese medicine is a useful and promising alternative strategy for treatment of Sjogren's syndrome: A review. Journal of Integrative Medicine, 2021, 19(3): 191-202.
[14] Yi Xia, Lu-shao-bo Shi, Jing-hui Chang, Hua-zhang Miao, Dong Wang. Impact of the COVID-19 pandemic on intention to use traditional Chinese medicine: A cross-sectional study based on the theory of planned behavior. Journal of Integrative Medicine, 2021, 19(3): 219-225.
[15] Na Zhi, Qian Mo, Shuo Yang, Yuan-xing Qin, Hao Chen, Zeng-guang Wu, Cai-hong Lan, Jun Zhang, Yin-long Li. Treatment of pulmonary fibrosis in one convalescent patient with corona virus disease 2019 by oral traditional Chinese medicine decoction: A case report. Journal of Integrative Medicine, 2021, 19(2): 185-190.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] Wei-xiong Liang. Problems-solving strategies in clinical treatment guideline for traditional Chinese medicine and integrative medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 1-4
[2] Zhao-guo Li. Discussion on English translation of commonly used sentences in traditional Chinese medicine: part one. Journal of Chinese Integrative Medicine, 2008, 6(1): 107-110
[3] Jun Hu, Jian-ping Liu. Non-invasive physical treatments for chronic/recurrent headache. Journal of Chinese Integrative Medicine, 2008, 6(1): 31
[4] Xue-mei Liu, Qi-fu Huang, Yun-ling Zhang, Jin-li Lou, Hong-sheng Liu, Hong Zheng. Effects of Tribulus terrestris L. saponion on apoptosis of cortical neurons induced by hypoxia-reoxygenation in rats. Journal of Chinese Integrative Medicine, 2008, 6(1): 45-50
[5] Daniel Weber, Janelle M Wheat, Geoffrey M Currie. Inflammation and cancer: Tumor initiation, progression and metastasis,and Chinese botanical medicines. Journal of Chinese Integrative Medicine, 2010, 8(11): 1006-1013
[6] Hong Liu , Guo-liang Zhang, Li Shen , Zhen Zeng, Bao-luo Zhou, Cheng-hai Liu, Guang Nie . Application and evaluation of a pseudotyped virus assay for screening herbs for anti-H5Nl avian influenza virus. Journal of Chinese Integrative Medicine, 2010, 8(11): 1036-1040
[7] Zhao-guo Li . A discussion of English translation of 1995 and 1997 Chinese National Standards of Traditional Chinese Medical Terminologies for Clinical Diagnosis and Treatment. Journal of Chinese Integrative Medicine, 2010, 8(11): 1090-1096
[8] Rui Jin, Bing Zhang. A complexity analysis of Chinese herbal property theory: the multiple formations of herbal property (Part 1). Journal of Chinese Integrative Medicine, 2012, 10(11): 1198-1205
[9] Hui-min Liu, Xian-bo Wang, Yu-juan Chang, Li-li Gu. Systematic review and meta-analysis of randomized controlled trials of integrative medicine therapy for treatment of chronic severe hepatitis. Journal of Chinese Integrative Medicine, 2012, 10(11): 1211-1228
[10] Liang-ping Hu, Xiao-lei Bao. Three-factor designs unable to examine the interactions (Part 2). Journal of Chinese Integrative Medicine, 2012, 10(11): 1229-1232